Stockholders’ Equity | Note 9 – Stockholders’ Equity The Company has authorized 100,000,000 90,000,000 0.000001 10,000,000 0.000001 Series B Preferred Stock Pursuant to the Exchange Agreement (see Note 5), the Holder agreed to exchange the Prior Notes for 230,375 0.000001 93,750 3.00 Shares of the Series B Preferred Stock is convertible at any time at the option of the holder thereof into shares of Common Stock at an initial conversion price of $ 3.00 Notes to Consolidated Financial Statements For Year Ended December 31, 2021 and 2020 The Series B Preferred Stock is subject to mandatory redemption in full at a redemption price initially equal to $ 10.00 10 If, at any time while the Series B Preferred Stock is outstanding, the Company completes any single public offering or private placement of its equity, equity-linked or debt securities (each, a “Future Transaction”), the holders of the Series B Preferred Stock may, in their sole discretion, elect to apply all, or any portion, of the then outstanding Preferred Stock and any accrued but unpaid dividends, as purchase consideration for such Future Transaction. The conversion price applicable to such conversion shall equal seventy percent ( 70 Common Stock During the year ended December 31, 2021, the Company: ● issued 100,0000 0.50 50,000 ● issued 333,250 95,324 ● issued 1,273,050 1,348,525 ● issued 600 ● issued 1,000,000 500,000 ● issued an aggregate of 256,250 1,145,768 ● issued 825,000 3,240,600 3,240,600 During the year ended December 31, 2020, the Company sold an aggregate of 2,553,571 275,000 125,000 25,000 Notes to Consolidated Financial Statements For Year Ended December 31, 2021 and 2020 Stock Options The following is a summary of stock option activity: Summary of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, December 31, 2019 300,000 $ 8.00 1.00 $ - Granted 4,040,000 1.62 Forfeited (1,800,000 ) 4.67 Exercised - Outstanding, December 31, 2020 2,540,000 $ 0.22 4.52 $ 1,074,245 Granted 310,000 0.85 Forfeited (401,475 ) 0.22 Exercised (1,681,775 ) 0.230 Outstanding, December 31, 2021 766,750 $ 0.44 3.71 $ 162,791 Exercisable, December 31, 2021 503,250 $ 0.53 3.76 $ 98,937 The exercise price for options outstanding and exercisable at December 31, 2021: Schedule of Options Outstanding by Exercise Price Range Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 20,000 $ 0.210 20,000 $ 0.210 516,750 0.215 310,125 0.215 15,000 0.220 5,000 0.220 155,000 0.530 108,125 0.530 20,000 0.940 20,000 0.940 20,000 2.120 20,000 2.120 20,000 3.800 20,000 3.800 766,750 503,250 For options granted during the year ended December 31, 2021 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 0.82 0.85 For options granted during the year ended December 31, 2020 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 0.211 0.215 1.11 4.00 Notes to Consolidated Financial Statements For Year Ended December 31, 2021 and 2020 The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $ 391,661 739,973 63,112 The assumptions used during the year ended December 31, 2021 and 2020 in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows: Schedule of Fair Value of Options Granted Assumptions 2021 2020 Risk-free interest rate 0.33 0.99 % 0.28 1.59 % Expected life of the options 5.0 5.0 Expected volatility 180 195 % 195 212 % Expected dividend yield 0 % 0 % Warrants The following is a summary of warrant activity: Summary of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, December 31, 2019 1,631,250 $ 4.08 3.38 $ Granted - Forfeited - Exercised - Outstanding, December 31, 2020 1,631,250 $ 4.08 2.38 $ - Granted 2,287,500 2.01 Forfeited - Exercised - Outstanding, December 31, 2021 3,918,750 $ 2.87 3.17 $ - Exercisable, December 31, 2021 3,918,750 $ 2.87 3.17 $ - The exercise price for warrants outstanding at December 31, 2021: Schedule of Warrants Outstanding by Exercise Price Range Outstanding and Exercisable Number of Exercise Warrants Price 900,000 $ 0.93 450,000 2.10 937,500 3.00 1,500,000 4.00 131,250 5.00 3,918,750 Notes to Consolidated Financial Statements For Year Ended December 31, 2021 and 2020 In connection with a convertible note discussed in Note 6, the Company has issued an aggregate of 937,500 warrants. The fair value of the warrants was determined to be $ 1,823,926 , using a Black-Scholes model, and has been recorded as financing costs in the accompanying statements of operations for the year ended December 31, 2021. The Company used the following assumptions in determining the fair value: Schedule of Fair Value of Options Granted Assumptions Risk-free interest rate 0.76 1.25 % Expected life of the options 5 Expected volatility 180 190 % Expected dividend yield 0 % In connection with a note payable discussed in Note 5, the Company has issued an aggregate of 900,000 791,921 Schedule of Fair Value of Options Granted Assumptions Risk-free interest rate 1.08 % Expected life of the options 5 Expected volatility 190 % Expected dividend yield 0 % |